Octreotide Reduces Vitreous Hemorrhage and Loss of Visual Acuity Risk in Patients with High-Risk Proliferative Diabetic Retinopathy

Boehm, B. O.; Lang, Gerhard K.; Jehle, Peter; Feldman, Bernard F.; Lang, Gabriele E.

doi:10.1055/s-2001-15282

Cited by 81 publications

(45 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Consequently, therapeutic strategies for diabetic retinopathy are currently focusing on the identification of pathways and receptors which would be able to antagonize VEGF-, IGF-1-, bFGF-or hypoxiadependent action on endothelial cell proliferation. Promising candidates for such an action are somatostatin and its receptors (Boehm et al 2001). The family of seven transmembrane domain G protein-coupled somatostatin receptors comprises five members termed SSTR1-5, which bind somatostatin 14 and somatostatin 28 as physiological ligands (van Hagen et al 2000.…”

Section: Introductionmentioning

confidence: 99%

Octreotide prevents growth factor-induced proliferation of bovine retinal endothelial cells under hypoxia

Baldysiak-Figiel

Lang²,

Kampmeier³

et al. 2004

Journal of Endocrinology

View full text Add to dashboard Cite

Ocular diseases such as proliferative diabetic retinopathy are the major cause of blindness in industrialized countries. The main pathologic features of these diseases are hypoxia and overproduction of growth factors resulting in pathologic proliferation of endothelial cells and new vessel formation. Particularly, hypoxia and growth factors, such as VEGF, IGF-1, bFGF and TGF 2 , show a complex interaction in the onset and progression of the diseases. Therefore, to date, most therapeutic strategies for proliferative retinopathies have targeted proliferation of endothelial cells evoked by growth factors. Recently, a synthetic analog of somatostatin, octreotide, has been shown to inhibit the proliferation of various cells in vitro, including endothelial cells. In this study, we have investigated the proliferative response of bovine retinal endothelial cells (BREC) to growth factors under hypoxic conditions and the modulation by octreotide. We found a dose-dependent increase of cell proliferation with VEGF, IGF-1 and bFGF, and inhibition of hypoxia-induced cell proliferation with TGF 2 . Moreover, growth factorinduced, but not hypoxia-induced, cell proliferation was attenuated in the presence of octreotide. In contrast, TGF 2 abolished hypoxia-induced BREC proliferation. Similar to octreotide BIM23027, a somatastatin receptor subtype 2 (SSTR2) receptor agonist was able to attenuate the growth factor-induced proliferation of BREC expressing mRNA and protein for SSTR2. Therefore, we postulate that octreotide exerts its effects mainly through binding to the SSTR2. Taken together, our findings point to octreotide as a promising candidate for the treatment of eye disorders involving growth factor-dependent proliferation of endothelial cells.

show abstract

Section: Introductionmentioning

confidence: 99%

Octreotide prevents growth factor-induced proliferation of bovine retinal endothelial cells under hypoxia

Baldysiak-Figiel

Lang²,

Kampmeier³

et al. 2004

Journal of Endocrinology

View full text Add to dashboard Cite

show abstract

“…Böhm et al [11] showed in a study on 18 patients with persistent proliferative DR with vitreous hemorrhage after laser treatment a significantly reduced incidence of vitreous hemorrhages and number of vitrectomies in the group treated with octreotide. In the treated group of 9 patients 78% showed an improvement in contrast to the control group.…”

Section: Pharmacological Treatment Of Drmentioning

confidence: 99%

Pharmacological Treatment of Diabetic Retinopathy

Lang

2007

Ophthalmologica

View full text Add to dashboard Cite

Despite the better options of controlling diabetes mellitus and although the prognosis of diabetic retinopathy has markedly improved by laser treatment and vitreoretinal surgery, diabetic retinopathy still is the leading cause of blindness in working age people in industrialized countries. Little has changed in the last decades regarding the prognosis of ocular complications in diabetes mellitus. We therefore need better tools and new therapeutic approaches for the prevention and treatment of diabetic ocular complications. Newer therapeutic options are directed at the causative mechanisms of diabetic retinopathy. Experimental and clinical evidence suggests that pharmacological compounds like somatostatin analogues and protein kinase C (PKC) inhibitors may be effective in the treatment of diabetic retinopathy. Chronic overproduction of growth hormone and insulin-like growth factor 1 play an important role in the pathogenesis of diabetic retinopathy. In the treatment of diabetic retinopathy somatostatin receptors are the targets of somatostatin analogues like octreotide. Octreotide has shown to be a promising treatment of diabetic retinopathy and diabetic macular edema. One important pathomechanism in the development of diabetic retinopathy is the activation of PKC induced by high glucose due to an increased diacylglycerol level. The selective PKC-β inhibitor ruboxistaurin mesylate enables a new therapeutical approach for the treatment of diabetic retinopathy. Ongoing prospective clinical trials investigate whether the treatment with the specific PKC-β inhibitor can prevent the progression of diabetic retinopathy and diabetic macular edema.

show abstract

“…Two pilot studies have reported that patients with severe NPDR or early PDR receiving intramuscular administration of somatostatin analogs were less likely to require panretinal photocoagulation [91,92]. Currently, a European phase II/III study is evaluating the effects of topically administrated neuroprotective substances somatostatin and brimonidine in patients with NPDR [93].…”

Section: Proliferative Diabetic Retinopathy (Pdr) and Nonproliferativmentioning

confidence: 99%

New Therapeutic Approaches in Diabetic Retinopathy

et al. 2015

View full text Add to dashboard Cite

■ AbstractDiabetic retinopathy is a common microvascular complication of diabetes mellitus. It affects a substantial proportion of US adults over age 40. The condition is a leading cause of visual loss. Much attention has been given to expanding the role of current treatments along with investigating various novel therapies and drug delivery methods. In the treatment of diabetic macular edema (DME), intravitreal pharmacotherapies, especially anti-vascular endothelial growth factor (anti-VEGF) agents, have gained popularity. Currently, anti-VEGF agents are often used as first-line agents in centerinvolved DME, with recent data suggesting that among these agents, aflibercept leads to better visual outcomes in patients with worse baseline visual acuities. While photocoagulation remains the standard treatment for proliferative diabetic retinopathy (PDR), recent FDA approvals of ranibizumab and aflibercept in the management of diabetic retinopathy associated with DME may suggest a potential for pharmacologic treatments of PDR as well. Novel therapies, including small interfering RNAs, chemokines, kallikreinkinin inhibitors, and various anti-angiogenic agents, are currently being evaluated for the management of diabetic retinopathy and DME. In addition to these strategies, novel drug delivery methods such as sustained-release implants and refillable reservoir implants are either under active evaluation or have recently gained FDA approval. This review provides an update on the novel developments in the treatment of diabetic retinopathy.

show abstract

Octreotide Reduces Vitreous Hemorrhage and Loss of Visual Acuity Risk in Patients with High-Risk Proliferative Diabetic Retinopathy

Abstract: In diabetics with high-risk proliferative retinopathy after full scatter laser coagulation, octreotide reduced the number of vitreous hemorrhages, preserving visual acuity.

Cited by 81 publications

References 9 publications

Octreotide prevents growth factor-induced proliferation of bovine retinal endothelial cells under hypoxia

Octreotide prevents growth factor-induced proliferation of bovine retinal endothelial cells under hypoxia

Pharmacological Treatment of Diabetic Retinopathy

New Therapeutic Approaches in Diabetic Retinopathy

Contact Info

Product

Resources

About